<DOC>
	<DOCNO>NCT01966419</DOCNO>
	<brief_summary>The purpose study determine whether ornithine phenylacetate speed recovery acute hepatic encephalopathy episode require hospitalization cirrhotic patient .</brief_summary>
	<brief_title>Phase 2B Efficacy/Safety Ornithine Phenylacetate Hospitalized Cirrhotic Patients With Hepatic Encephalopathy ( STOP-HE )</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study ornithine phenylacetate ( OCR-002 ) administer intravenously hospitalize patient cirrhosis , hyperammonemia , acute episode hepatic encephalopathy administer top standard care treatment .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Hyperammonemia</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<criteria>Hospitalized acute episode hepatic encephalopathy complication cirrhosis Elevated venous ammonia Renal failure serum creatinine &gt; 3 mg/dL need dialysis Molecular Adsorbent Recirculation System utilized Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>hyperammonemia</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>ornithine phenylacetate</keyword>
	<keyword>OCR-002</keyword>
</DOC>